



26TH JUNE 2020 | Number 7

XENOTHERA NEWS

Official news bulletin for XAV-19



EDITORIAL

by **Odile DUVAUX, President of XENOTHERA**

Soon it will be summer, which for some means the sea and waves. The gentle waves of the Mediterranean, the surf of Gascony or elsewhere ... waves are “in”! So “in” that it’s in all the newspapers: the first wave, the second wave, and there’s no talk yet of a third wave. Once again, let’s admit honestly that nobody knows if or when these waves are likely to arrive. Neither the Chinese nor the Americans, nor indeed anyone else. Epidemiologists’ models speak of the past, but they cannot predict the future with certainty. So let’s accept that we don’t know, and clear up any misunderstandings right now. Of course, we have absolutely no desire to see the epidemic resume, not now and not in the autumn, and it would be terrible to return to lockdown, to the “Plan Blanc” (French hospital emergency plan), and other health emergency protocols. There is no question of wishing there were more cases, and developing a treatment does not mean that we’re hoping for more sick people. We are not waiting impatiently for these waves to arrive Only those on the beaches ...

MAIN FOCUS

Update on XAV-19 news

XENOTHERA is moving forward, step by step, and building, brick by brick. Our most recent news is the certification of the clinical batch of XAV19, i.e. its certified conformity to the required pharmaceutical specifications. This does not come as a surprise, but is yet one more point highlighting the quality of the work carried out by the XENOTHERA team. So we are now waiting to hear back from the authorities (ANSM, CPP) with the all-important authorization for a clinical trial, allowing us to start.





In parallel, we are preparing the next steps, specifically more clinical batches for the following stages. We continue to produce serum (before purification) and currently have enough to treat several hundred patients, with the goal of reaching a thousand by the end of the summer.

TESTIMONY

Support of XENOTHERA

This week we invite you to listen to the very personal testimony of Bernard Jaubert. An economist and sociologist by training, he founded DMJ Consultants in partnership with Odile Duvaux. He has supported her for many years and is following XENOTHERA with great interest.

[Click on the image to hear his testimony:](#)





In the media...

The highlight of the past few days was the communication regarding funding of the XAV-19 treatment. This announcement was relayed by the media. Following is a selection of articles and reports:

(Click on the logos to access articles and reports)



télé.nantes
loire-atlantique
BOX 30 TNT 31



Find our latest press releases:

- [XENOTHERA launches support campaign to finalise treatment for coronavirus infections, including Covid-19 \(31th March 2020\)](#)
- [LFB signs agreement with biotech XENOTHERA \(15th April 2020\)](#)
- [The search for Covid-19 treatments: how can the antibodies developed by the French biotech XENOTHERA help? \(in french\) \(30th April 2020\)](#)
- [XENOTHERA secures funding of more than 7 million euros for its anti-Covid treatment and the acceleration of its product portfolio \(15th June 2020\)](#)

ABOUT XENOTHERA :

XENOTHERA, created in 2014, is a Nantes-based biotech company which develops “humanized” polyclonal antibodies. Their technological platform is based on dual expertise in animal genetics and a mastery of immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant for transplants, has been in clinical trials since 2019. XENOTHERA is part of the Nantes scientific, medical and academic environment and is supported by the Pays de la Loire region’s Atlanpole competitiveness cluster. Since its creation, the company has raised 6 million euros in equity and has received support from the BPI.

For more information go to www.xenothera.com

Follow XENOTHERA on social media :



Contact :

XENOTHERA

1 rue Vauban - 44 000 Nantes
xenothera@izsogood.co